{
    "clinical_study": {
        "@rank": "26797", 
        "arm_group": [
            {
                "arm_group_label": "BGF MDI (PT010) Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "BGF MDI Dose 1 taken as 2 inhalations"
            }, 
            {
                "arm_group_label": "BGF MDI (PT010) Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "BGF MDI Dose 2 taken as 2 inhalations"
            }, 
            {
                "arm_group_label": "BGF MDI (PT010) Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "BGF MDI Dose 3 taken as 2 inhalations"
            }, 
            {
                "arm_group_label": "GFF MDI (PT003)", 
                "arm_group_type": "Active Comparator", 
                "description": "GFF MDI (PT003) taken as 2 inhalations"
            }, 
            {
                "arm_group_label": "Symbicort MDI Dose 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Symbicort MDI taken as 2 inhalations"
            }, 
            {
                "arm_group_label": "Symbicort MDI Dose 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Symbicort MDI Dose 2 taken as 2 inhalations"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period,\n      Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of\n      Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose\n      of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of\n      Symbicort\u00ae Inhalation Aerosol in Healthy Volunteers. The primary objective of the study is\n      to determine a dose of budesonide that when formulated with glycopyrronium and formoterol\n      fumarate in BGF MDI provides comparable systemic exposure [pharmacokinetics (PK)] to\n      budesonide following administration of Symbicort MDI."
        }, 
        "brief_title": "Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "condition_browse": {
            "mesh_term": "Respiratory Aspiration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide signed written informed consent form\n\n          -  18 and 45 years (inclusive)\n\n          -  Healthy subject confirmed by a thorough medical history and physical examination,\n             ECG, vital signs and clinical laboratory tests\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential must agree to use medically acceptable contraception\n\n          -  Body mass index (BMI) between 18.5 and 32 kg/m2 (inclusive) and a minimum weight of\n             50 kg at the screening visit\n\n          -  Results of complete laboratory analyses should be within the normal range or\n             determined to be not clinically significant by the Investigator\n\n        Exclusion Criteria:\n\n          -  Pregnancy, nursing female subjects, or subjects trying to conceive\n\n          -  Clinically significant medical conditions\n\n          -  History of ECG abnormalities\n\n          -  Symptomatic prostatic hypertrophy, bladder neck obstruction, or urinary retention\n\n          -  Known diagnosis of glaucoma\n\n          -  Known or suspected history of substance-related disorders within 1 year of screening\n\n          -  Treatment with an investigational drug within 30 days or five half-lives (whichever\n             is longer) prior to screening period\n\n          -  Hypersensitivity to lactose or any drug or component of the formulation(s) used in\n             this study\n\n          -  Positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen\n             (HbsAg) or positive hepatitis C antibody at screening.\n\n          -  Major surgery within four weeks or minor surgery within 2 weeks of drug\n             administration\n\n          -  Any other condition and/or situation that causes the Investigator to deem a subject\n             unsuitable for study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980615", 
            "org_study_id": "PT010001-00"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 2", 
                    "BGF MDI (PT010) Dose 3", 
                    "GFF MDI (PT003)", 
                    "Symbicort MDI Dose 1", 
                    "Symbicort MDI Dose 2"
                ], 
                "intervention_name": "Inhaled BGF (PT010) Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 1", 
                    "BGF MDI (PT010) Dose 3", 
                    "GFF MDI (PT003)", 
                    "Symbicort MDI Dose 1", 
                    "Symbicort MDI Dose 2"
                ], 
                "intervention_name": "Inhaled BGF (PT010) Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 1", 
                    "BGF MDI (PT010) Dose 2", 
                    "GFF MDI (PT003)", 
                    "Symbicort MDI Dose 1", 
                    "Symbicort MDI Dose 2"
                ], 
                "intervention_name": "Inhaled BGF (PT010) Dose 3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 1", 
                    "BGF MDI (PT010) Dose 2", 
                    "BGF MDI (PT010) Dose 3", 
                    "Symbicort MDI Dose 1", 
                    "Symbicort MDI Dose 2"
                ], 
                "intervention_name": "Inhaled GFF (PT003)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 1", 
                    "BGF MDI (PT010) Dose 2", 
                    "BGF MDI (PT010) Dose 3", 
                    "GFF MDI (PT003)", 
                    "Symbicort MDI Dose 2"
                ], 
                "intervention_name": "Inhaled Symbicort Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BGF MDI (PT010) Dose 1", 
                    "BGF MDI (PT010) Dose 2", 
                    "BGF MDI (PT010) Dose 3", 
                    "GFF MDI (PT003)", 
                    "Symbicort MDI Dose 1"
                ], 
                "intervention_name": "Inhaled Symbicort Dose 2", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glycopyrrolate", 
                "Formoterol", 
                "Budesonide", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Pearl Therapeutics Study Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort\u00ae Inhalation Aerosol in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pearl Therapeutics, Inc.", 
            "last_name": "Colin Reisner, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort Inhalation Aerosol.\nThe safety of BGF MDI, Symbicort MDI and GFF MDI will be assessed from physical examination findings, adverse event (AE) reporting including SAE reporting, vital signs (blood pressure, heart rate, respiratory rate and body temperature), clinical laboratory values (hematology, biochemistry, and urinalysis), and findings from 12-lead safety electrocardiograms (ECGs).", 
            "measure": "Overall safety of BGF, GFF, and Symbicort MDI based on the group of outcome measures for safety.", 
            "safety_issue": "Yes", 
            "time_frame": "12 hours following study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), Symbicort MDI and GFF MDI.\nThe PK of BGF MDI, Symbicort MDI and GFF MDI will be assessed and compared from plasma concentrations of each drug.\nPK parameters at all doses will include Cmax, tmax, t\u00bd, AUC0-12, AUC0-t, CL/F, Vd/F, and \u03bbz. Other PK parameters may be calculated, as appropriate.", 
            "measure": "Overall pharmacokinetic profile of BGF, GFF, and Symbicort MDI based on the group of outcome measures for pharmacokinetics.", 
            "safety_issue": "No", 
            "time_frame": "12 hours following study drug administration"
        }, 
        "source": "Pearl Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pearl Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}